Literature DB >> 24528005

Factors predicting microinvasion in Ductal Carcinoma in situ.

Sibel Ozkan-Gurdal1, Neslihan Cabioglu, Beyza Ozcinar, Mahmut Muslumanoglu, Vahit Ozmen, Mustafa Kecer, Ekrem Yavuz, Abdullah Igci.   

Abstract

BACKGROUND: Whether sentinel lymph node biopsy (SLNB) should be performed in patients with pure ductal carcinoma in situ (DCIS) of the breast has been a question of debate over the last decade. The aim of this study was to identify factors associated with microinvasive disease and determine the criteria for performing SLNB in patients with DCIS.
MATERIALS AND METHODS: 125 patients with DCIS who underwent surgery between January 2000 and December 2008 were reviewed to identify factors associated with DCIS and DCIS with microinvasion (DCISM).
RESULTS: 88 patients (70.4%) had pure DCIS and 37 (29.6%) had DCISM. Among 33 DCIS patients who underwent SLNB, one patient (3.3%) was found to have isolated tumor cells in her biopsy, whereas 1 of 14 (37.8%) patients with DCISM had micrometastasis (7.1%). Similarly, of 16 patients (18.2%) with pure DCIS and axillary lymph node dissection (ALND) without SLNB, none had lymph node metastasis. Furthermore, of 20 patients with DCISM and ALND, only one (5%) had metastasis. In multivariate analysis, the presence of comedo necrosis [relative risk (RR)=4.1, 95% confidence interval (CI)=1.6-10.6, P=0.004], and hormone receptor (ER or PR) negativity (RR=4.0, 95%CI=1.5-11, P=0.007), were found to be significantly associated with microinvasion.
CONCLUSIONS: Our findings suggest patients presenting with a preoperative diagnosis of DCIS associated with comedo necrosis or hormone receptor negativity are more likely to have a microinvasive component in definitive pathology following surgery, and should be considered for SLNB procedure along with patients who will undergo mastectomy due to DCIS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24528005     DOI: 10.7314/apjcp.2014.15.1.55

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  14 in total

1.  Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences.

Authors:  Xiao Sun; Hao Li; Yan-Bing Liu; Zheng-Bo Zhou; Peng Chen; Tong Zhao; Chun-Jian Wang; Zhao-Peng Zhang; Peng-Fei Qiu; Yong-Sheng Wang
Journal:  Oncol Lett       Date:  2015-07-10       Impact factor: 2.967

2.  Imaging features that distinguish pure ductal carcinoma in situ (DCIS) from DCIS with microinvasion.

Authors:  Hongli Wang; Jinjiang Lin; Jianguo Lai; Cui Tan; Yaping Yang; Ran Gu; Xiaofang Jiang; Fengtao Liu; Yue Hu; Fengxi Su
Journal:  Mol Clin Oncol       Date:  2019-07-03

3.  N-Acetylglucosaminyltransferase III (GnT-III) but not N-Acetylgalactosaminyltransferase-6 and 8 are Differentially Expressed in Invasive and In Situ Ductal Carcinoma of the Breast.

Authors:  Antônio Felix da Silva Filho; Gabriela Souto Vieira-de-Mello; Petra Barros Dos Santos; Moacyr Jesus Barreto de Melo Rêgo; Alfredo Ribeiro-Silva; Eduardo Isidoro Carneiro Beltrão
Journal:  Pathol Oncol Res       Date:  2019-01-28       Impact factor: 3.201

4.  Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.

Authors:  Xiao-Yang Chen; Aye Aye Thike; Valerie Cui Yun Koh; Nur Diyana Md Nasir; Boon Huat Bay; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2020-11-02       Impact factor: 4.064

5.  Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.

Authors:  Koji Takada; Shinichiro Kashiwagi; Yuka Asano; Wataru Goto; Tamami Morisaki; Katsuyuki Takahashi; Hisakazu Fujita; Tsutomu Takashima; Shuhei Tomita; Kosei Hirakawa; Masaichi Ohira
Journal:  BMC Cancer       Date:  2020-06-03       Impact factor: 4.430

6.  Factors associated with upstaging in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy.

Authors:  Jing Si; Benlong Yang; Rong Guo; Naisi Huang; Chenlian Quan; Linxiaoxi Ma; Bingqiu Xiu; Yun Cao; Yue Tang; Linxiao Shen; Jiajian Chen; Jiong Wu
Journal:  Cancer Biol Med       Date:  2019-05       Impact factor: 4.248

7.  Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery?

Authors:  Hai-Fei Niu; Li-Juan Wei; Jin-Pu Yu; Zhen Lian; Jing Zhao; Zi-Zheng Wu; Jun-Tian Liu
Journal:  Cancer Biol Med       Date:  2016-03       Impact factor: 4.248

8.  Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion.

Authors:  Zhi-Bin Wan; Hong-Yi Gao; Lian Wei; An-Qin Zhang; Jiang-Yu Zhang; Yi Wang; Dong-Dong Wang; Yan Zhang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

9.  Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study.

Authors:  Serena Bertozzi; Carla Cedolini; Ambrogio P Londero; Barbara Baita; Francesco Giacomuzzi; Decio Capobianco; Marta Tortelli; Alessandro Uzzau; Laura Mariuzzi; Andrea Risaliti
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

10.  Axillary evaluation is not warranted in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy.

Authors:  Jing Si; Rong Guo; Naisi Huang; Bingqiu Xiu; Qi Zhang; Weiru Chi; Jiong Wu
Journal:  Cancer Med       Date:  2019-10-29       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.